Intrakines, modified intracellular chemokines, offer a novel strategy to prevent cellular entry of HIV-1 by blocking the surface expression of HIV-1 co-receptors. To investigate potential clinical applications of the RANTES-intrakine, we explored the use of HIV-1-based lentiviral vectors for therapeutic gene transfer into T-lymphocytes. RANTES-intrakine genes can be efficiently transduced into primary human Tlymphocytes by lentiviral vectors, especially when human Tlymphocytes were stimulated with CD3 and CD28 antibodies. The transduced T cells showed decreased surface expression of the chemokine receptor CCR-5, as well as CCR-1 and CCR-3. This lentivirus-mediated approach to
Introduction
Human immunodeficiency virus type-1 (HIV-1) infection is initiated by the interaction of virion glycoproteins with a CD4 and a chemokine receptor.
1,2 R5 (macrophage, M) tropic HIV-1 infects macrophages and primary CD4 + T cells mainly by using the CC-chemokine receptor 5 (CCR-5) as its principal co-receptor. [3] [4] [5] [6] [7] [8] 
X4 (T cell line-tropic) HIV-1 strains infect CD4
+ T cells primarily by using the co-receptor CXCR-4. Although other chemokine receptors can also participate in HIV-1 infection, CCR-5 has a critical role in both the initial infectious process and the progression of the disease. 1, 2, 8 It is used by almost all Mtropic HIV-1 strains, regardless of their viral genetic subtype, and by the related lentiviruses HIV-2 and simian immunodeficiency virus (SIV). 1, 2 Persons with a homozygous 32 base-pair deletion in the CCR-5 gene, resulting in a truncated protein that remains within the cell, are highly resistant to HIV-1 infection. [9] [10] [11] [12] [13] [14] This alteration does not affect the health of homozygous carriers, indicating that its functions are dispensable. [9] [10] [11] [12] [13] [14] Thus, CCR-5 affords an attractive therapeutic target, especially for patients in the early stage of infection.
In our previous studies, we developed a novel 'intrakine' strategy to block the transport of newly synthesized 
intrakine gene transfer protected human T-lymphocytes from infection by a variety of R5-tropic HIV-1 strains. A quantitative real-time PCR assay, developed to monitor cells for HIV entry and persistence, revealed persistent low copy numbers of proviral HIV DNA in RANTES intrakine-transduced Tlymphocytes during 3-week culture, suggesting that viruses produced from infected untransduced cell populations were unable to infect the surrounding transduced T-lymphocytes. We conclude that targeting HIV-1 co-receptors to block virus entry with lentiviral vectors is an attractive approach to the control of HIV-1 infection.
Gene Therapy (2002) 9, 889-897. doi:10.1038/sj.gt.3301711 chemokine receptors to the cell surface. 15, 16 T cells were transduced by oncoretroviral vectors that expressed the RANTES-intrakine, a modified CC-chemokine with an endoplasmatic reticulum (ER) retention signal (KDEL) that prevents secretion. The intrakine binds to the newly synthesized CCR-5 molecules and traps them in the ER, where they are degraded. RANTES-intrakine expressing T cells were found to resist M-tropic HIV-1 infection, while maintaining basal biological features. 15, 16 These studies indicate that human lymphocytes can be genetically modified to express intrakines capable of blocking HIV infection.
To investigate potential clinical applications for the RANTES-intrakine strategy, we explored the use of HIV-1-based lentiviral vectors for therapeutic gene transfer into T cells. Such vectors have several compelling features: for example, they efficiently transduce either proliferating or quiescent cells and promote sustained expression of the transgene through their stable integration into the host cell genome. [17] [18] [19] [20] In this study, we tested the feasibility of using lentiviral vectors for intrakine gene therapy. We employed a quantitative real-time PCR assay to determine the ability of intrakines to inhibit HIV-1 infection.
Results

Lentiviral vector construction, and intrakine expression driven by lentiviral vectors
Two intrakine lentiviral vectors, TRIP RANTES-SK and LOX RANTES-SK, were generated. In the TRIP RANTES-SK vector, the intrakine expression was driven by the CMV promoter, whereas the intrakine expression was driven by the promoter of the human elongation factor EF1␣ gene in LOX RANTES-SK. We first tested their ability to express RANTES-intrakines, using radiolabeling and immunoprecipitation analysis. As shown in Figure 1b , the RANTES-intrakine proteins were predominately found in the lysate of cells transfected with the plasmid DNA pTRIP RANTES-SK and pLOX RANTES-SK. No corresponding protein band was detected in the cells transfected with a control pLOX IRES GFP. Higher levels of RANTES-intrakines appeared to be produced in the pLOX RANTES-SK transfected cells with a density of 453 of the specific protein band than in pTRIP RANTES-SK transfected cells with a density of 391 for the RANTES-SEKDEL protein band. To quantitatively assess the production of RANTES-intrakines in human T cells by the different vectors, we generated recombinant pseudotyped lentiviruses by transient calcium-phosphate co-transfection of 293T cells with the HIV-derived packaging construct pCMV⌬R8.91, pMD.G which expresses glycoprotein G of the vesicular stomatitis virus (VSV-G), and the lentiviral transfer vectors. 18 were transduced with TRIP hrGFP, TRIP RANTES-SK or LOX RANTES-SK at the same vector concentration of 1 × 10 5 IU/ml, resulting in a transduction rate of 3-5% hrGFP-positive T cells 2 weeks after lentivector transduction. The low vector concentration was chosen in order to maximize the probability that each transgene expressing T cell only had integrated one transgene copy. The transduced (GFP+) T cells were isolated by FACS. RANTES concentrations in the transduced T cells were measured by ELISA. As shown in Figure 2 , higher levels of RANTES-intrakine (27 500 pg/mg cellular protein) were expressed in the LOX RANTES-SK transduced PM-1 cells than in cells transduced with TRIP RANTES-SK (8000 pg/mg cellular protein), indicating that the human elongation factor EF1␣ promoter mediates stronger expression of RANTES-intrakine in human T cells. These results are in accordance with two previously published papers, demonstrating an enhanced eGFP expression in human T cells transduced with EF1␣-containing lentivectors as compared with corresponding vectors containing an internal CMV-promoter. 18, 21 Thus, LOX RANTES-SK was used for further analysis.
Surface chemokine expression on intrakine-transduced T cells
We next investigated whether lentivirus-mediated intrakine gene transfer into human T cells would down-regulate CCR-5 surface expression. PM-1 cells transduced with LOX RANTES-SK or LOX IRES GFP were studied by FACS. As shown in Figure 3a , the cells expressed comparable levels of CXC-chemokine receptor (CXCR)-4, CD3, and CD4 after transduction with either LOX RANTES-SK or LOX IRES GFP. By contrast, surface expression of CCR-5 on T cells transduced with LOX RANTES-SK was decreased by comparison with the result obtained with LOX IRES GFP (Figure 3a) . Although CCR-5 is a major co-receptor for HIV infection, other chemokine receptors, such as CCR-3 and CCR-1, can also act as co-receptors. 2, 4, 8 Thus, down-regulation of multiple chemokine receptors might produce broader anti-HIV activities. Since RANTES binds promiscuously to CCR-1, CCR-3, and CCR-5, [22] [23] [24] we predicted that the 
Figure 3 Immunophenotyping of lentivirally transduced T-lymphocytes. Transduced PM-1 cells were incubated with biotinylated mouse monoclonal antibodies against CCR-5, CXCR-4, CD3, and CD4 (a) or against CCR-3 and CCR-1 (b), followed by incubation with APC-labeled streptavidin. To determine non-specific background staining appropriate isotype controls were used. After staining, the cells were analyzed by FACS.
other two co-receptors might also be down-regulated by RANTES-intrakine. As shown in Figure 3b , T-lymphocytes transduced with LOX RANTES-SK showed decreased surface expression of CCR-3 and CCR-1 relative to their expression on the T cells transduced with LOX IRES GFP.
Lentiviral vector-mediated intrakine transfer
Several T cell culture methods have been used to stimulate and expand human T cells in vitro for HIV gene therapy. One such method relies on high-dose IL-2, together with PHA or anti-CD3, while a newer method uses antibodies to CD3 and CD28 to co-stimulate CD4 + and CD8 + T cells. The latter approach not only allows ex vivo proliferation of CD4 + T cells, but also transiently renders CD4 + T cells resistant to infection with R5-tropic HIV through down-regulation of the HIV fusion co-receptor CCR-5. 25, 26 We used FACS analysis to assess the transduction efficiency of the LOX GFP WPRE vector on primary human T cells stimulated by the methods described above. PBLs from different donors were stimulated with rhIL-2 (20 IU/ml) and PHA (5 g/ml) or with anti-CD3 and CD28 antibodies for 3 days. As shown in Figure 4 , 61-69% of primary T cells from different donors stimulated by the anti-CD3 and CD28 antibodies were GFPpositive 1 week after lentiviral transduction at a vector concentration of 5 × 10 7 IU/ml (MOI of 100), compared with only 27-42% of primary T cells stimulated by IL-2 and PHA. The efficiency of transduction depended on the concentration of the vector. Percentages of GFP+ T cells decreased during the first 2 weeks after transduction, then remained constant. These results indicate that lentiviral vectors can efficiently transduce human primary T cells and that the T cell culture method of co-stimulation relying on anti-CD3 and CD28 antibodies would be preferable to other means of co-stimulation in T cell-mediated gene therapy for HIV-1 infection.
Inhibition of HIV infection of human T cells
To assess the anti-HIV-1 protection afforded by lentivirus-mediated intrakine gene transfer into human T
Figure 4 Lentiviral transduction of primary human T-lymphocytes. Human peripheral blood lymphocytes were stimulated with phytohemagglutinin (PHA) and interleukin-2 (IL-2) or with immobilized anti-CD3 and anti-CD28 antibodies. After lentiviral transduction of the lymphocytes with LOX GFP WPRE at the indicated vector concentrations, gene transfer efficiency was determined by FACS. Experiments were performed in triplicate and mean (s.e.m.) numbers of GFP+ cells 1 and 2 weeks after transduction are shown.
cells, we transduced PM-1 cells with LOX RANTES-SK or LOX IRES GFP, and isolated the transduced T cells by FACS. After isolation, over 95% of the PM-1 cell population were positive for GFP. Transduced or untransduced PM-1 cells were infected with the same amounts of different strains of HIV-1 viruses (MOI of 0.01). High levels of p24 protein were detected in the untransduced PM-1 and LOX IRES GFP transduced PM-1 cultures. In contrast, only low or background levels of p24 were detected in LOX RANTES-SK-transduced cultures after infection with R5-tropic strains of HIV (Figure 5a ). However, the RANTES-SK transduced PM-1 cells were still susceptible to infection by the XR4-tropic IIIB virus, which uses CXCR-4 as its co-receptor. In addition, the intrakine-transduced T cells remained resistant to R5-tropic HIV-1 infection at higher MOI (Figure 5b) .
We further tested whether lentivirus-mediated intrakine gene transfer would protect primary human PBL from HIV-1 infection. Human PBLs from different donors were stimulated with IL-2 and PHA, because the preferred stimulation method with anti-CD3 and CD28 antibodies would transiently down-regulate CCR-5 on T cells, causing the intrakine experiment to be difficult to interpret. PBLs were transduced with LOX RANTES-SK or LOX IRES GFP, isolated by FACS and equally infected with an M-tropic HIV virus (SF 162 ) at an MOI of 0.01. Virus production in the cultures was quantified by measuring p24 levels. As shown in Figure 6 , only background levels of p24 were detected in cultures of RANTESintrakine transduced PBLs, contrasted with high levels in the GFP vector-transduced cultures. Taken together, these findings demonstrate the resistance of RANTES intrakine-transduced T-lymphocytes to R5-tropic HIV-1 infection.
Quantitative determination of viral entry and persistence in intrakine-transduced T cells
A major concern with the use of the intrakine approach is whether a complete blockade of surface expression of chemokine co-receptors is required to block HIV-1 entry into susceptible cells. Although down-regulation of chemokine receptors on T cells by RANTES-intrakine lentiviral vectors was achieved with intrakines, there were still residual amounts of CCR-5 molecules on the cell surface ( Figure 3) . Therefore, we employed a quantitative PCR method to determine HIV entry and persistence in intrakine-transduced T cells. PM-1 cells that expressed high levels of CCR-5 were transduced with LOX RANTES-SK or LOX IRES GFP, and then isolated with a purity of over 97%. The transduced cells were infected overnight with HIV viruses (JR-CSF) at an MOI of 0.01, washed and cultured in fresh medium. HIV proviral DNA loads at different time-points after infection were determined by quantitative real-time PCR method. Serial dilutions of the T lymphoblastoid cell line 8E5, which contains a single proviral genome of HIV-LAV per cell, were used as a standard to determine proviral copy numbers per reaction. For precise quantification, the input level of cellular DNA in the samples was measured in a second exogenous control experiment, using the same amount of DNA and quantitative real-time PCR with primers and a probe specific for C-reactive protein (CRP) DNA. 27 As shown in Figure 7 , a low copy number of proviral HIV DNA (44 copies/ng genomic DNA) was detected in the LOX RANTES-SK transduced PM-1 cells 3 days after infection and the HIV proviral DNA copy numbers stayed relatively constant during the 3-week culture. By contrast, significantly higher copy numbers of proviral HIV DNA (743 copies/ng genomic DNA) were detected in the LOX IRES-GFP transduced lymphocytes 3 days after infection and these numbers increased dramatically, as high as 5277 copies/ng genomic DNA over time ( Figure 7 ).
Discussion
Combination anti-HIV drug therapy decreases mortality and slows disease progression, but fails to eradicate the infection. Moreover, viral resistance to chemotherapy affects up to 30-50% of all patients on the HAART regimen. [28] [29] [30] Immune reconstitution with genetically modified T cells, combined with anti-viral drugs, may hold the key to successful long-term control of HIV-1 infection. Although the clinical efficiency of gene therapy for HIV-1 infection remains unproven, the intrakine strategy described in this report has the potential to generate a stronger, and longer-lasting anti-HIV action than that achieved with administration of chemokines or small molecules. Candidate target cells for anti-HIV-1 intrakine gene therapy include hematopoietic stem cells and T cells. The latter are attractive because they are relatively easy to transduce and can proliferate in vitro as well as in vivo, and because the stem cell/thymus T cell pathway may be inefficient in adults. Gene therapy clinical trials have demonstrated that infusion of transduced T cells does not cause any apparent adverse side-effects, and that the transduced T cells can survive in vivo for many months. [31] [32] [33] T cells transduced with an anti-HIV-1 gene M10 appeared to have a survival advantage in vivo compared with controls. 31 Genetically marked T cells were also found not only to persist in vivo for weeks to months, but also to expand in HIV-infected patients. It was also reported that a T cell expansion process reliably yields 2 to 3 × 10 10 gene-modified T cells within 2 weeks of in vitro culture. 33 In that study, modified T cells persisted in the blood of all patients at high levels (1-3% of PBMCs) throughout the 8-week observation period. 33 Extended 34, 35 although the safety concerns for lentiviral vectors still remain. 36 The intrakine that blocks HIV entry is unique, since other anti-HIV gene therapy approach is targeted at the replication of HIV after virus infection of host T cells. Although it could not be expected to transduce all or even the majority of T cells in HIV-1-infected patients, the lentivirus-mediated RANTES intrakine strategy would still produce beneficial effects if the transduced T cells survived for extended periods and maintained their usual functions, including the ability to proliferate and expand in response to antigen stimulation, would eventually constitute a large fraction of the total T cell population. Repeated infusions of large numbers of transduced T cells would reconstitute the immune system and maintain adequate immune function, while resisting HIV-1 infection.
A key concern with the intrakine approach is whether complete blockade of surface expression of chemokine co-receptors is required to block HIV-1 entry into susceptible cells. Although down-regulation of chemokine receptors on T cells has been achieved with oncoretroviral vectors expressing the RANTES intrakine gene, 15, 16 it was unclear whether such intrakines were potent enough to down-regulate chemokine receptors and to block HIV-1 entry into activated T cells. Here, we show that lentivirally delivered RANTES-intrakine will significantly lower CCR-5 surface expression on activated T cells, although the transduced cells still retained residuals of CCR-5 on the surface membrane. Accordingly, we devised a quantitative PCR assay that would allow us to determine whether this slight expression of CCR-5 was adequate to support HIV-1 entry. Thus, intrakine-transduced and control T cells were found to contain low copy numbers of HIV proviral DNA, indicating infection by the virus. However, in contrast to control T cells transduced with a blank HIV vector, the proviral DNA copy numbers remained at a low level during the culture period. We attribute this result to HIV-1 infection of the small fraction of untransduced T cells in the total T cell population, which by FACS was not entirely transduced. If the intrakine-transduced T cells had been susceptible to HIV infection, either via cell-free viruses or cell-cell transmission, we should have seen a rapid increase of HIV-1 proviral copy numbers, given the HIV replication rates 895 and the large number of intrakine-transduced T cells in the culture. The constant copy number of HIV proviral DNA in the intrakine transduced T cells also indicated that the viruses produced from infected cells were unable to infect the surrounding intrakine transduced T cells. Thus, blocking HIV-1 entry into T cells can be achieved by down-regulating CCR-5 to a level below that needed to support virus entry. A study to determine this threshold is under way.
Since more than nine chemokine receptors, other than the principal CCR-5 and CXCR-4 receptors can function as HIV-1 co-receptors in vitro, a potential problem for any therapy targeting chemokine co-receptors is that blocking one chemokine receptor may drive HIV-1 to use alternative co-receptors.
1,2 However, since CCR-5 is critical for HIV-1 infection, the virus may not easily adapt to the use of other co-receptors. Indeed, it was reported that the frequency with which CXCR-4-tropic viruses emerge in individuals who are heterozygous for the CCR-5⌬32 allele is no greater than in individuals with wild-type alleles, despite the reduced CCR-5 expression associated with the CCR-5⌬32 heterozygous genotype. 37 Moreover, there have been several reports of using small molecules or chemokines to block HIV-1 infection and to decrease viral load in HIV-infected individuals. [38] [39] [40] [41] Hence, targeting HIV-1 co-receptors to block virus entry is a reasonable approach to the control of HIV-1 infection, thus warranting further evaluation in animal model and human trials.
Materials and methods
Construction of lentiviral transfer vectors
The two HIV transfer vectors used in this study were pTRIP ⌬U3 CMV eGFP and pLOX EF1␣ GFP WPRE, 17, 18 both of which are self-inactivating (SIN vectors) and contain a 400 bp deletion in the U3 region of the 3' long terminal repeat (LTR), which removes the transcriptionally active sequence. 42 pTRIP ⌬U3 CMV GFP comprises an internal cytomegalovirus (CMV) promoter, whereas pLOX EF1␣ GFP WPRE contains the promoter of the human elongation factor EF1␣ gene. 18 The plasmid pTRIP ⌬U3 CMV GFP contains a 178-bp fragment encompassing the central polypurine tract (cPPT) and the central termination sequence (CTS) in the unique ClaI site of the original pHR' backbone. 19 The same fragment was amplified by polymerase chain reaction (PCR; sense primer:
5'-ATACATCGATACAAATGGCAGTATTC ATCC-3', anti-sense primer: 5'-TATATCGATCCAAA GTGGATCTCTGCTGTCCCTGT-3') and inserted in the ClaI site of pLOX EF1␣ GFP WPRE. In both vectors the eGFP and WPRE sequences were replaced by an internal ribosome entry site (IRES) sequence from the encephalomyocarditis virus genome and the humanized Renilla reniformis green fluorescent protein (hrGFP) reporter gene (Stratagene, La Jolla, CA, USA). The coding sequence of the human RANTES gene was 5'-linked with the Kozak consensus sequence and linked with a SEKDEL sequence 43 at the 3' end by PCR (sense primer: 5'-ATATGGATCCCGCCACCATGAAGGTCTC CGCGGCACGCCTCGC-3', anti-sense primer: 5'-ATA TACGCGTTCACAGCTCGTCCTTCTCGCTGCT-3'). Subsequently, the RANTES-SK (intrakine) gene was cloned into pTRIP CMV IRES hrGFP and pLOX EF1␣ IRES Gene Therapy hrGFP. The resultant bi-cistronic vectors pTRIP RANTES-SK and pLOX RANTES-SK ( Figure 1a) were confirmed by DNA sequencing.
Analysis of protein expression
To label and immunoprecipitate recombinant proteins, we transfected Cos-1 cells with 1 g of plasmid DNA per well in a six-well plate, and 72 h later radiolabeled with 100 Ci of [ 35 S]cysteine/methionine for 2 h. The culture media (M) and cell lysates (C) were precipitated with an anti-human RANTES antibody (VL1, Biosource International, Camarillo, CA, USA) and Protein A beads (Sigma, St Louis, MO, USA). After heat denaturation, the radiolabeled proteins were separated by Tris/Tricine/SDS-PAGE and visualized by autoradiography. The density of the specific protein bands was quantified by by computer-assisted densitometry (Wincam 2.2 software).
Lentiviral vector production and titration
The HIV-derived packaging construct pCMV⌬R8.91, encodes the HIV-1 gag and pol precursors, as well as the regulatory proteins tat and rev. Glycoprotein G of the vesicular stomatitis virus (VSV-G) was expressed from the plasmid pMD.G. 18 Pseudotyped lentiviruses were produced by transient calcium-phosphate co-transfection of 293T cells with pCMV⌬R8.91, pMD.G, and the lentiviral transfer vectors. Viral supernatants were harvested 60-72 h after transfection, concentrated by two rounds of ultracentrifugation, and resuspended in serum-free RPMI 1640 culture medium. Viral titers were determined with 293T cells as previously described. 20 
Preparation of primary human T-lymphocytes
Peripheral blood mononuclear cells were purified from the fresh blood of healthy donors by Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation. Non-adherent peripheral blood leukocytes (PBLs) were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO 2 . They were stimulated for 3 days with recombinant human interleukin-2 (hIL-2, 20 IU/ml; Boehringer Roche, Indianapolis, IN, USA) and phytohemagglutinin (PHA-P, 5 g/ml; Sigma) or with an immobilized ␣CD3 antibody (HIT3a, 1 g/ml; Pharmingen) and an immobilized ␣CD28 antibody (CD28.2, 1 g/ml, Pharmingen) on nontissue culture-treated plates for 3 days, and then cultured in the presence of hIL-2 (20 IU/ml).
Lentiviral transduction and cell sorting of T-lymphocytes
Transductions of PM-1 cells and PBLs were performed on 48-well plates with addition of 5 g/ml Polybrene (Sigma). The cells were exposed to lentiviral concentrates at titers between 5 × 10 8 and 1 × 10 5 infectious units/ml at a density of 5 × 10 5 cells/ml. After 8 h of transduction, the cells were washed with phosphate-buffered saline (PBS) and further incubated in fresh tissue culture medium. In some experiments, transduced lymphoid cells expressing GFP were identified by their fluorescence profile and sorted on a Cytomation MoFlo instrument. As determined by trypan blue staining technique, the viability of cells after cell sorting was higher than 95%.
Flow cytometric analysis
Flow cytometric analyses were performed with a FACSCalibur apparatus and with CellQuest Software (Becton Dickinson, Mountain View, CA, USA). For immunophenotypic analysis, the T cells were labeled with allophycocyanin (APC)-conjugated monoclonal antibodies (mAbs) directed against the following antigens: CD4 (RPA-T4, Pharmingen), CD3 (SK7, Pharmingen), and CXCR-4 (12G5, Pharmingen). CCR-1 (H-52, Santa Cruz, Santa Cruz, CA, USA), CCR-3 (61828.111, R&D Systems, Minneapolis, MN, USA), and CCR-5 (45531.111, R&D Systems) were detected by a biotin-labeled antibody with subsequent staining with APC-labeled streptavidin (Pharmingen). Appropriate isotype controls were used in every experiment in order to determine non-specific background staining. After suitable FSC/SSC gating, 10 000 events were collected in channel FL-1 for GFP and channel FL-4 for APC.
Quantification of cellular RANTES protein PM-1 cells (5 × 10 5 ) were transduced with TRIP hrGFP, TRIP RANTES-SK, and LOX RANTES-SK at the same vector concentration of 1 × 10 5 IU/ml. Two weeks after transduction, GFP-expressing cells (3-5%) were isolated using a Cytomation MoFlo instrument. PM-1 cells were lysed with TNT-lysis buffer (25 mM TrisțCl, pH 7.4, 150 mM NaCl, 1% Triton X-100) and total protein concentration was determined by the Bradford protein assay using bovine serum albumin as a standard (BioRad, Hercules, CA, USA). The concentration of the RANTES (SEKDEL) protein in the cell lysates was quantified by a sandwich ELISA according to the manufacturer's manual (R&D Systems). 
HIV-1 infection and p24 assay
Quantification of proviral HIV-1 load by quantitative realtime PCR
DNA was extracted from cells by using the QIAamp Blood Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's recommendations. The concentration of DNA after extraction was measured by spectrophotometer (GeneQuant II, Amersham Pharmacia Biotech, Piscataway, NJ, USA). The proviral HIV-1 load in transduced cells, was measured with 5' nuclease PCR technology and the ABI PRISM 7700 Sequence Detection System (SDS; PE Applied Biosystems, Foster City, CA, USA) using primers and a probe specific for a 199-bp fragment of the HIV-1 pol gene. 44 The forward primer P1 (5'-TGGC-ATGGGTACCAGCACA-3'), the reverse primer P2 (5'-CTGGCTACTAT-TTCTTTTGCTA-3'), and the internal probe (5'-TTTATCTACCTGTTCATTTCCT-CCAATTCCTT-3') were used. TaqMan probes carried 6-carboxy fluorescein (FAM) as 5' reporter dye (Applied Biosystems). Serial 1:2-fold dilutions of the T lymphoblastoid cell line 8E5 (ATCC 8993), which contains a single proviral genome of HIV-LAV per cell, were used as a standard for the determination of proviral copy numbers per reaction. 500 ng of DNA was analyzed in duplicate for each sample. For precise quantification, the input level of cellular DNA in the samples was measured with the same amount of DNA in a second exogenous control real-time quantitative (RQ) PCR determination. For this purpose, the amplifiable amount of genomic DNA was quantified by RQ PCR analysis using primers and a probe specific for the C-reactive protein (CRP) DNA as described in detail elsewhere. 27 The PCR mixture for the HIV-1 or CRP DNA amplification consisted of 2 × TaqMan Universal Master Mix (PE Applied Biosystems), primers (300 nM concentration of each), 200 nM of the HIV-1 or CRP probe and template. The volume was adjusted to 50 l with nuclease-free water (Promega, Madison, WI, USA). The PCR consisted of 2 min at 50°C (inactivation of possible carry-over contamination by uracil N'-glycosylase (UNG)), 10 min at 95°C (UNG inactivation and activation of the DNA polymerase) and 40 two-step cycles of 15 s at 95°C and 60 s at 60°C. The normalized HIV-proviral levels in samples were expressed as HIV copy numbers per g of amplifiable genomic DNA.
